Actavis unit yanks another 94K Bystolic bottles as recall expands

Tracy Staton Actavis nabbed a big portfolio of branded products when it bought Forest Laboratories earlier this year. But it also inherited a quality-control problem. FiercePharma News

Novo Nordisk bets another $130M on diabetes R&D with new Danish hub

Damian Garde Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $ 130 million project that will expand its wide footprint in diabetes research. FierceBiotech ...

Baxter wins FDA approval for another hemophilia drug

Damian Garde Baxter widened its hemophilia franchise on the eve of its breakup, winning FDA approval for a drug that treats a rare form of the bleeding disorder. FierceBiotech News

Lilly says with new data, it will seek another approval for Cyramza next year

Eric Palmer Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to ...

Another Israeli biotech braves choppy IPO waters

John Carroll The latest batch of Israeli biotechs to hit Nasdaq hasn't been doing so well. But that hasn't deterred Foamix Pharmaceuticals from joining the tail end of the big ...

J&J, Pharmacyclics celebrate yet another nod for leukemia med Imbruvica

Tracy Staton Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic ...

UPDATED: Targacept’s litany of trial failures continues with yet another flop

John Carroll On Monday, Targacept reported that its midstage effort aimed at salvaging its lead drug flopped. Once partnered with AstraZeneca, which saw four late-stage studies for ...

Bayer’s Nexavar misses another study endpoint, this time for breast cancer

Eric Palmer Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.  FiercePharma News

Payer pushback aside, Sovaldi, and so Gilead, has another huge quarter

Eric Palmer Gilead Sciences' juggernaut, Sovaldi, keeps on rolling along despite the pushback from payers, politicians and health officials over the high price of the hepatitis ...

Bullish biotechs shoot for $400M in another big week for IPOs

Damian Garde After Sage Therapeutics staged a stellar debut on Friday, 6 more drug developers are expected to price IPOs this week, looking to buck some bearish trends in biotech and ...

GlaxoSmithKline and Theravance eye Phase III for another COPD contender

Damian Garde The blockbuster duo of GlaxoSmithKline and Theravance are pushing a new respiratory combo therapy into late-stage study, pooling the active ingredients from its last two ...

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...
Page 3 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS